ACS Chemical Biology · 2022 · 27 citations · 45 references
Life SciencesInfectious DiseasesMedicinal ChemistryDrug DiscoveryMolecular VirologyVirologyAntiviral AgentsAntiviral ImmunityAntiviral PharmacologyAntiviral TherapyVirus EntryAntiviral Signaling PathwaysAntiviral TherapeuticsHost-targeted AntiviralsKinase DomainsTherapeutic Targeting Of Viral EntryViral Entry InhibitorsViral Replication InhibitorsViral Therapeutic Targets
Inhibition of the protein kinase CSNK2 with any of 30 specific and selective inhibitors representing different chemotypes, blocked replication of pathogenic human, bat, and murine β-coronaviruses. The potency of in-cell CSNK2A target engagement across the set of inhibitors correlated with antiviral activity and genetic knockdown confirmed the essential role of the CSNK2 holoenzyme in β-coronavirus replication. Spike protein endocytosis was blocked by CSNK2A inhibition, indicating that antiviral activity was due in part to a suppression of viral entry. CSNK2A inhibition may be a viable target for the development of anti-SARS-like β-coronavirus drugs.
45
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan, Jiwan Ge, Jinfang Yu et al. · Nature · 2020 · 6.7K citations · Full text
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon, Gwendolyn Μ. Jang, Mehdi Bouhaddou et al. · Nature · 2020 · 4.9K citations · Full text
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj, Huihui Mou, Saskia L. Smits et al. · Nature · 2013 · 2.1K citations · Full text